SCHEMBL30730463

SCHEMBL30730463

Cc1nccnc1CC(=O)N1CCC(c2nc(-c3ccc(Cl)c(Cl)c3)no2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.51
TSHR P16473 2/20 0.51
ALOX15 P16050 1/20 0.51
MAPK1 P28482 1/20 0.51
SMN1; SMN2 Q16637 3/20 0.47
HTT P42858 2/20 0.47
ALDH1A1 P00352 1/20 0.47
POLB P06746 1/20 0.47
CYP3A4 P08684 1/20 0.47
MAPT P10636 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
TUBB4A P04350 1/20 0.45
TUBB P07437 1/20 0.45
TUBA3C P0DPH7 1/20 0.45
TUBA1B P68363 1/20 0.45
TUBA4A P68366 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32676704 0.89 LMNA (0.52) LMNATSHRALOX15MAPK1SMN1; SMN2
SCHEMBL30730713 0.86 LMNA (0.68) LMNATSHRALOX15MAPK1SMN1; SMN2
SCHEMBL30730623 0.86 LMNA (0.51) LMNATSHRALOX15MAPK1SMN1; SMN2
SCHEMBL30730443 0.85 LMNA (0.49) LMNATSHRALOX15MAPK1SMN1; SMN2
SCHEMBL30730570 0.84 LMNA (0.51) LMNATSHRALOX15MAPK1SMN1; SMN2
SCHEMBL32676997 0.84 LMNA (0.52) LMNATSHRALOX15MAPK1SMN1; SMN2
SCHEMBL30730586 0.82 LMNA (0.51) LMNATSHRALOX15MAPK1SMN1; SMN2
SCHEMBL30730527 0.81 LMNA (0.50) LMNATSHRALOX15MAPK1SMN1; SMN2
SCHEMBL30730535 0.81 TSHR (0.54) LMNATSHRALOX15MAPK1SMN1; SMN2
SCHEMBL32676830 0.80 LMNA (0.50) LMNATSHRALOX15MAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US claimed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO claimed
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US disclosed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE FNTB, PDE7A, TBL3 LMNA 1838/4885TSHR 620/4885ALOX15 2647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.